Cn /En

News Center

——

Company news

Industry news

InnoModels Biotechnology iHuPDX Platform

Author:

InnoModels

Release time:

2024-08-14

In the field of biomedicine, innovation is an important driving force for technological advancement and clinical application. With its iHuPDX (Individualized Human Patient-Derived Xenograft) platform, InnoModels Biotechnology (Beijing) Co., Ltd. is bringing unprecedented changes to cancer research and treatment. This platform not only demonstrates InnoModels' profound strength in the field of personalized medicine, but also provides new hope and possibilities for tumor treatment.
Core Advantages of iHuPDX Technology
iHuPDX technology is a xenotransplantation technology based on individual patient's tumor cells, the core of which lies in the establishment of a tumor model that is highly close to the actual situation of the patient. Cancer tissue samples are collected from patients and transplanted into animals such as mice to form individualized transplanted tumors. This highly individualized disease model can not only more accurately simulate the biological characteristics of the patient's tumor growth, metastasis, and drug response, but also provide doctors with an important basis for a comprehensive understanding of the patient's tumor characteristics.
Strong support for precision medicine
Traditional tumor models are often based on standardized cell lines or tissue samples, which cannot fully reflect the uniqueness of a patient's tumor. The iHuPDX platform, on the other hand, is derived directly from the patient's tumor cells, and is therefore able to more accurately simulate the actual condition of the patient's tumor. This technology provides an important basis for the development of personalized treatment plans, enabling physicians to select the most appropriate drug combinations and dosages for patients prior to treatment, thereby increasing the success rate of treatment and reducing unnecessary risks.

Accuracy of Drug Response Prediction
The iHuPDX platform also has significant advantages in drug response prediction. Due to the high degree of similarity between the model and the patient's tumor, researchers can test the response of different drugs on the model against a specific patient's tumor, thereby predicting the drug's efficacy and possible side effects in the patient. This predictive ability provides physicians with important decision support, allowing for more scientific and precise treatment planning.
Stability and Growth Rate of the Technology
The iHuPDX platform also excels in technology stability and growth rate. With advanced primary cell inoculation technology, the model is able to achieve early and uniform growth, ensuring that efficacy experiments are conducted within the optimal window. At the same time, the homogenization of the same batch of samples is ensured through the modeling of cell suspensions, resulting in a high degree of consistency in the growth rate and biological characteristics of the models. This stability not only ensures the reliability of experimental results, but also reduces experimental and time costs.
New breakthrough in tumor immunity research
InnoModels Biotechnology also combined the iHuPDX platform with the humanized model of the PBMC immune system, providing a more ideal model for tumor immunity research. This combination enables the model to simulate not only tumor growth and drug response, but also the interaction between the tumor and the immune system. This provides a powerful tool for a deeper understanding of tumor immune mechanisms and the development of new immunotherapies, driving further development in the field of tumor therapy.
Future Prospects of InnoModels Biotechnology
InnoModels Biotechnology (Beijing) Co., Ltd. is confident in the future of the iHuPDX platform. With the deepening of biomedical research and continuous technological innovation, iHuPDX platform is expected to play a more important role in the field of personalized medicine. In the future, we can expect to see more research results and application scenarios related to iHuPDX technology, which will bring more accurate and effective treatment solutions to patients.
Since its establishment, InnoModels Biotechnology has been committed to promoting innovation in the field of biomedicine and has established several unique modeling platforms, including the iHuPDX platform. The Company has not only made remarkable achievements in the field of new drug development, but also helped the industry develop at a rapid pace by providing the most clinically referenced preclinical research support to innovators in oncology and tumor immunotherapy.
In summary, with its high degree of individualization, accurate drug response prediction and stable and reliable growth characteristics, the iHuPDX platform of InnoModels Biotechnology has become an important support for personalized precision medicine. In the future, with the continuous development and improvement of the technology, iHuPDX platform will play an even more important role in the field of cancer treatment, bringing hope and gospel to more patients.

Applications of InnoModels Biotechnology's CDX modeling

Introduction to the InnoModels Biotechnology Bowel Disease (IBD) Modeling Platform

Applications of InnoModels Biotechnology's CDX modeling

Introduction to the InnoModels Biotechnology Bowel Disease (IBD) Modeling Platform

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License